China Pharmaceutical announced that its wholly-owned subsidiary Tianfang Pharmaceutical received two "Drug Registration Certificates" for Sacubitril-Valsartan Sodium Tablets approved and issued by the National Medical Products Administration. The drug is the world's first angiotensin receptor neprilysin inhibitor (ARNI) approved for marketing, used to treat adult patients with chronic heart failure with reduced ejection fraction.